
William F. Wiley, MD, shares key takeaways from his presentation on binocularity and stereoacuity

William F. Wiley, MD, shares key takeaways from his presentation on binocularity and stereoacuity

Dr Neda Nikpoor discusses Light Adjustable Lenses and the implications for clinicians at ASCRS 2024

At ASCRS 2024, Aurion Biotech's Global VP Eris Jordan previews upcoming clinical data from North America and Asia

Jascha Wendelstein, MD, discusses the outcomes of a study comparing K and TK measurements

At ASCRS 2024, Oliver Findl, MD, provides an update on the ESCRS IOL calculator and new tools to come this year

Ahead of the ASCRS 2024 meeting, TheiaNova CEO Carissa Fonseca, PhD, pitched a novel keratoconus treatment

At the 2024 ASCRS meeting, Anthony Wallace details the presentations and educational programmes from Bausch + Lomb

At the ASCRS meeting in Boston, Dan Tran, MD, details his presentation on incision quality and clinical outcomes of femtosecond laser

At ASCRS in Boston, Paul Harasymowycz, MD shared a decade's worth of data on MIGS procedures for primary open-angle glaucoma

Adam Muzychuk, MD, BSc, FRCSC, discusses his ASCRS 2024 presentation on toric lens use for patients with low astigmatism

Greg Kunst, CEO of Aurion Biotech, discusses AURN001, a novel cell therapy targeting corneal endothelial disease

At ASCRS2024, George O. Waring IV, MD, FACS, provides an overview of his presentation highlighting outcomes for LASIK performed using an updated laser ablation algorithm

Filomena Ribeiro, MD, PhD, FEBO, discusses her presentation on neuroadaptation following the ASCRS Refractive Day

Sean Hanlon, CEO of CoFi, details the patient and provider benefits of recent CareCredit integration

Rich Small, CEO of Neurotech Pharmaceuticals, provides an update on the months ahead for NT-501 encapsulated cell therapy

Andrew G. Lee, MD, expresses his perspective regarding the necessity of lumbar puncture for all individuals with idiopathic intracranial hypertension, highlighting the importance of clinical judgment and treatment approaches.

A case study emphasises the shifting paradigm in clinical best practices

Good news for patients: use of anti-complement therapies have caused the growth rate of GA lesions to decrease

Retina specialists Giuseppe Querques, MD, PhD, and Paolo Lanzetta, MD, debate at the Congress on Controversies in Ophthalmology

At this year's Congress on Controversies in Ophthalmology, keynote speaker Ursula Schmidt-Erfurth, MD, addressed the clinical use of artificial intelligence

Dr Baruch Kuppermann discusses interim results from the first in-human Phase 2 RIPPLE-1 Trial of a dexamethasone implant for diabetic macular oedema and retinal vein occlusion.

Ramin Tadayoni, MD, PhD, highlights data from the BALATON and COMINO Phase 3 studies about faricimab

Robyn Guymer, MBBS, PhD, reported the Voyager study’s preliminary data at the 2024 Angiogenesis, Exudation, and Degeneration conference

Dr Jennifer Lim reveals new data on Angiopoietin-2 inhibition and insights on clinical trial design

Anat Loewenstein, MD, illuminates the outcomes of using an AI-based fluid quantification for remote retina monitoring and analysis

Dr Carl Regillo provided an overview of topline results – and a deep dive into subgroup analyses – of DAVIO 2 trial data

Sydney M Crago, editor of Modern Retina, talks with Arshad M Khanani, MD, MA, FASRS, about the expanded efficacy data from the GATHER 2 trial, presented at the 2024 Angiogenesis Symposium

EODM may be an ideal candidate for development of complement gene therapy due to the high-impact genetic variants

Researchers aimed to develop a translational map to understand how advanced imaging biomarkers manifest in typical diagnostic imaging

The afternoon sessions begin after lunch and continue well into the evening at the Angiogenesis, Exudation, and Degeneration 2024 meeting